Search Results - "Das, Sonia G"

  • Showing 1 - 20 results of 20
Refine Results
  1. 1

    A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer by Mineva, Nora D, Pianetti, Stefania, Das, Sonia G, Srinivasan, Srimathi, Billiald, Nicolas M, Sonenshein, Gail E

    Published in Pharmaceutics (01-04-2024)
    “…New targeted treatments are urgently needed to improve triple-negative breast cancer (TNBC) patient survival. Previously, we identified the cell surface…”
    Get full text
    Journal Article
  2. 2

    A Facile Asymmetric Synthesis of Either Enantiomer of 2-Substituted Pyrrolidines by Rajender Reddy, Leleti, Das, Sonia G, Liu, Yugang, Prashad, Mahavir

    Published in Journal of organic chemistry (02-04-2010)
    “…A new and general method for asymmetric synthesis of either enantiomer of 2-substituted pyrrolidines from a single starting material is described. Reductive…”
    Get full text
    Journal Article
  3. 3

    Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia by Hermanson, David L, Das, Sonia G, Li, Yunfang, Xing, Chengguo

    Published in Molecular pharmacology (01-08-2013)
    “…Drug resistance is a serious challenge in cancer treatment and can be acquired through multiple mechanisms. These molecular changes may introduce varied…”
    Get more information
    Journal Article
  4. 4

    miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells by Das, Sonia G, Romagnoli, Mathilde, Mineva, Nora D, Barillé-Nion, Sophie, Jézéquel, Pascal, Campone, Mario, Sonenshein, Gail E

    Published in Breast cancer research : BCR (02-04-2016)
    “…ADAM8 (a disintegrin and metalloproteinase 8) protein promotes the invasive and metastatic phenotype of triple-negative breast cancer (TNBC) cells. High ADAM8…”
    Get full text
    Journal Article
  5. 5

    Putative Identification of New Phragmaline-Type Limonoids from the Leaves of Swietenia macrophylla King: A Case Study Using Mass Spectrometry-Based Molecular Networking by Reis, José, Gomes, Paulo, Sá, Paulo, Pamplona, Sônia, Silva, Consuelo, da Silva, Maria, Bishayee, Anupam, da Silva, Milton

    Published in Molecules (Basel, Switzerland) (01-11-2023)
    “…Swietenia macrophylla King is a plant commonly known as Brazilian mahogany. The wood from its stem is highly prized for its exceptional quality, while its…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Structure−Activity Relationship and Molecular Mechanisms of Ethyl 2-Amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4H-chromene-3-carboxylate (sHA 14-1) and Its Analogues by Das, Sonia G, Doshi, Jignesh M, Tian, Defeng, Addo, Sadiya N, Srinivasan, Balasubramanian, Hermanson, David L, Xing, Chengguo

    Published in Journal of medicinal chemistry (08-10-2009)
    “…Rapid development of multiple drug resistance against current therapies is a major barrier in the treatment of cancer. Therefore, anticancer agents that can…”
    Get full text
    Journal Article
  8. 8
  9. 9

    sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell by Tian, Defeng, Das, Sonia G, Doshi, Jignesh M, Peng, Jun, Lin, Jialing, Xing, Chengguo

    Published in Cancer letters (08-02-2008)
    “…Abstract HA 14-1, a small-molecule antagonist against anti-apoptotic Bcl-2 proteins, was demonstrated to induce selective cytotoxicity toward malignant cells…”
    Get full text
    Journal Article
  10. 10

    Ethyl 2‑Amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)‑4H‑chromene-3-carboxylate (CXL017): A Novel Scaffold That Resensitizes Multidrug Resistant Leukemia Cells to Chemotherapy by Das, Sonia G, Hermanson, David L, Bleeker, Nicholas, Lowman, Xazmin, Li, Yunfang, Kelekar, Ameeta, Xing, Chengguo

    Published in ACS chemical biology (15-02-2013)
    “…Multidrug resistance (MDR) is a major hurdle in the treatment of cancer, and there is a pressing need for new therapies. We have recently developed ethyl…”
    Get full text
    Journal Article
  11. 11

    Abstract 23: Antibody targeting of ADAM8 for treatment of triple-negative breast cancer by Das, Sonia G., Pianetti, Stefania, Sonenshein, Gail E., Mineva, Nora D.

    Published in Cancer research (Chicago, Ill.) (01-07-2017)
    “…Abstract Triple-Negative Breast Cancer (TNBC) accounts for 25% of breast cancer deaths. Current therapeutic options are restricted to chemotherapy (CT) and…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Abstract B166: MicroRNAs downstream of ADAM8 as therapeutic targets and non-invasive biomarkers for triple-negative breast cancer by Das, Sonia G., Romagnoli, Mathilde, Mineva, Nora D., Sonenshein, Gail E.

    Published in Molecular cancer therapeutics (01-11-2013)
    “…Abstract Triple-negative breast cancer (TNBC) represents ∼20% of breast cancers, is highly aggressive and lacks targeted therapies due to the absence of…”
    Get full text
    Journal Article
  17. 17

    Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) – a novel scaffold that re-sensitizes multidrug resistant leukemia cells to chemotherapy by Das, Sonia G., Hermanson, David L., Bleeker, Nicholas, Lowman, Xazmin, Li, Yunfang, Kelekar, Ameeta, Xing, Chengguo

    Published in ACS chemical biology (05-11-2012)
    “…Multidrug resistance (MDR) is a major hurdle in the treatment of cancer and there is a pressing need for new therapies. We have recently developed ethyl…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20